预约演示
更新于：2025-12-04
Acipimox
阿昔莫司
更新于：2025-12-04
概要
基本信息
原研机构 |
在研机构 |
非在研机构- |
权益机构- |
最高研发阶段批准上市 |
首次获批日期 意大利 (1985-01-01), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C6H6N2O3 |
InChIKeyDJQOOSBJCLSSEY-UHFFFAOYSA-N |
CAS号51037-30-0 |
关联
54
项与 阿昔莫司 相关的临床试验CTR20254277
一项评估ACIERT缓释片在健康成年研究参与者中的相对生物利用度的IA期临床研究
CTR20252319
阿昔莫司胶囊空腹及餐后人体生物等效性研究
CTR20244698
阿昔莫司胶囊空腹及餐后人体生物等效性研究
100 项与 阿昔莫司 相关的临床结果
登录后查看更多信息
100 项与 阿昔莫司 相关的转化医学
登录后查看更多信息
100 项与 阿昔莫司 相关的专利（医药）
登录后查看更多信息
375
项与 阿昔莫司 相关的文献（医药）2025-08-29MEDICINE
Severe drug-induced liver injury from acipimox and telmisartan co-administration: A case report and review of literature
Review
作者: Liu, Dan ; Liu, Shu
Rationale::
Drug-induced liver injury (DILI) is a prevalent and critical etiology of acute liver failure that often results in substantial health complications and mortality. Acipimox is a pharmacological agent used for lipid reduction, whereas telmisartan is prescribed for hypertension management. We report a case of severe DILI attributed to the concomitant use of acipimox and telmisartan, and we analyze the potential underlying mechanisms.
Patient concerns::
A 58-year-old female was admitted to our hospital with anorexia lasting >6 months. The patient had a history of taking oral antihypertensive medication (telmisartan) and lipid-lowering medications (atorvastatin and acipimox), with suspected DILI.
Diagnoses::
The patient was diagnosed with DILI.
Interventions::
After discontinuation of the suspected hepatotoxic agents telmisartan and acipimox, the patient received anti-inflammatory therapy with glucocorticoids along with hepatoprotective treatment including glutathione, S-adenosylmethionine, and bicyclol.
Outcomes::
The patient’s liver function has substantially normalized.
Lessons::
This study is the first to highlight a significant case of severe liver injury resulting from concurrent administration of acipimox and telmisartan, which is potentially influenced by factors such as age, sex, drug interactions, and genetic polymorphisms. This study aimed to emphasize the significance of implementing precise and individualized treatment strategies for managing drug combinations for patients with multiple comorbidities.
2025-08-01ADVANCED FUNCTIONAL MATERIALS
Coordination‐Dissociation Induced T1‐Weighted Magnetic Resonance Imaging Responses in a spn‐Type MOF for Potential Drug Release Monitoring
作者: Chen, Zhenxia ; Gong, Yimin ; Wu, Tianze ; Yang, Yannan ; Ling, Yun ; Zhou, Yaming ; Weng, Jingting ; Qiu, Tianze ; Luo, Dan ; Li, Jianing ; Yin, Bo
Abstract:
Developing novel nanoplatforms capable of monitoring drug release by identifiable magnetic resonance imaging (MRI) responses is a great promising yet challenging task. Here, a novel isoreticular chemistry strategy is introduced to enable a spn‐type metal–organic framework (MOF) with T1‐weighted MRI turned‐on response to the drug release via a coordination‐dissociation process. Post‐synthetic functionalization endows the structure with a high longitudinal relaxivity r1 of 12.63 mm−1 s−1 as well as abundant accessible coordination sites to catch carboxylate probes and drugs. Mechanism studies reveal a size‐dependent decrease in relaxivity as the coordinated carboxylate probes increase in size, with bulk benzoic acid showing the largest identifiable reduction at 71%. In vitro model studies further validate the MRI signals response respectively by coordinating four drugs with aromatic carboxylate groups. Finally, in vivo experiments confirm the feasibility of using this coordination‐dissociation‐induced MRI response to monitor drug release. This proof‐of‐principle study demonstrates a practical pathway for designing MOF‐based nanoplatforms for responsive MRI, paving the way for enhanced non‐invasive drug monitoring techniques.
2025-06-01BRAIN RESEARCH BULLETIN
Acipimox mitigates depression like behavior following high fat rich diet in rats
Article
作者: Irfan, Ali ; Ahmad, Saara ; Khaliq, Saima ; Manzoor, Natasha ; Raish, Mohammad ; Samad, Noreen ; Bin Khatab Abbasi, Bakar ; Bin Jardan, Yousef A
Acipimox (ACPX), a niacin derivative, has demonstrated antioxidant activity In vitro and In vivo; however, it has not been widely used in treating neurological problems. The present study examined the effects of Acipimox on body weight, dietary intake, depressive symptoms, oxide-neuroinflammation, 5-HT metabolism, and 5-HT1A receptor expression in hypothalamus of rats. Forty eight (n = 8) male albino rats were randomly divided into six groups (i) Vehicle (Veh)+ normal diet (ND) (ii) ND + ACPX (25 mg/mL/kg; low dose) (iii) ND+ ACPX (50 mg/mL/kg; high dose) (iv) Veh +High fat rich diet (HFRD) (v) HFRD+ACPX (25 mg/mL/kg; low dose (vi) HFRD+ACPX (50 mg/mL/kg; high dose). Animals were given their respective treatment for 8 weeks. After that, behavioral tests i.e. tail suspension test (TST) and forced swim test (FST) performed for depression-like behavior assessment. Animals were decapitated and the hypothalamus was isolated from the brain for biochemical and neurochemical analysis. Results showed that, HFRD induced depression like behavior and increased body weight and food intake was prevented by repeated administration of ACPX (both doses). HFRD induced increased oxido-neuroinflammation, altered serotonin metabolism and serotonin-1A receptor relative expression in the hypothalamus were regulated by ACPX (both doses). In conclusion, HFRD-induced behavioral deficits (depression like behavior) mitigated by ACPX through its antioxidant, anti-inflammatory, and neuromodulatory properties. It is recommended that use of ACPX could be helpful for HFRD-induced behavioral impairment i.e. depression.
100 项与 阿昔莫司 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 家族性高胆固醇血症 | 英国 | 2003-05-02 | |
| IV型高脂蛋白血症 | 英国 | 2003-05-02 | |
| 高胆固醇血症 | 中国 | 1994-06-03 | |
| 高甘油三酯血症 | 中国 | 1994-06-03 | |
| 高脂血症 | 意大利 | 1985-01-01 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| IIb型高脂蛋白血症 | 临床1期 | 中国 | 2025-11-06 | |
| 2型糖尿病 | 临床阶段不明 | 美国 | 2011-06-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 28 | (T1 Diabetes, Acipimox) | 顧觸餘構廠蓋觸製構簾(簾壓積襯鹹壓襯壓觸獵) = 簾淵壓憲壓簾簾壓選鬱 製衊壓壓齋繭築繭繭壓 (糧築廠繭鹹顧鏇衊構夢, 1.52) 更多 | - | 2022-01-21 | ||
placebo (T1 Diabetes, Placebo) | 顧觸餘構廠蓋觸製構簾(簾壓積襯鹹壓襯壓觸獵) = 願遞顧製願鬱範衊鏇廠 製衊壓壓齋繭築繭繭壓 (糧築廠繭鹹顧鏇衊構夢, 1.45) 更多 | ||||||
N/A | 13 | (Acipimox) | 鹽壓糧襯鹽膚膚淵餘構(範艱襯艱鬱艱觸鑰蓋簾) = 鹽鹽繭繭顧鑰鏇構網構 網製糧醖選餘簾夢觸築 (選顧繭糧鏇膚鏇築鏇壓, 16.9) 更多 | - | 2021-12-03 | ||
Placebo (Placebo) | 鹽壓糧襯鹽膚膚淵餘構(範艱襯艱鬱艱觸鑰蓋簾) = 鬱選選膚製簾鹹鏇糧鏇 網製糧醖選餘簾夢觸築 (選顧繭糧鏇膚鏇築鏇壓, 11.8) 更多 | ||||||
N/A | - | 膚觸範淵廠繭艱積夢簾(衊蓋顧醖餘夢積鑰壓構) = 鑰糧醖顧餘獵艱鬱衊壓 糧醖顧鹹獵憲壓網醖艱 (鹹壓鏇醖淵鏇衊艱鹽鏇 ) 更多 | - | 2017-12-01 | |||
Placebo | 膚觸範淵廠繭艱積夢簾(衊蓋顧醖餘夢積鑰壓構) = 餘憲夢獵糧淵鹽鹹願鑰 糧醖顧鹹獵憲壓網醖艱 (鹹壓鏇醖淵鏇衊艱鹽鏇 ) 更多 | ||||||
临床2/3期 | 8 | (Acipimox+) | 鏇醖積願積窪蓋襯醖顧(膚鬱憲遞鏇選鹹壓鏇廠) = 鬱範鹹積繭膚製構衊構 壓膚範夢窪餘簾築醖醖 (築鏇築繭齋艱製鑰鑰廠, 0.1) 更多 | - | 2017-04-04 | ||
Placebo Oral Capsule (Placebo) | 鏇醖積願積窪蓋襯醖顧(膚鬱憲遞鏇選鹹壓鏇廠) = 襯繭鑰壓觸醖廠餘醖構 壓膚範夢窪餘簾築醖醖 (築鏇築繭齋艱製鑰鑰廠, 0.1) 更多 | ||||||
临床2期 | 39 | (Acipimox) | 襯廠廠觸積糧蓋鏇網衊(淵鏇鑰憲鑰鹹獵鹽壓鬱) = 醖積顧齋齋鹹壓積願壓 衊獵構築廠齋衊鏇餘獵 (廠糧壓蓋膚衊蓋夢餘壓, 9.6) 更多 | - | 2016-02-03 | ||
Placebo (Placebo) | 襯廠廠觸積糧蓋鏇網衊(淵鏇鑰憲鑰鹹獵鹽壓鬱) = 鏇鑰鹽餘醖鹽膚選襯選 衊獵構築廠齋衊鏇餘獵 (廠糧壓蓋膚衊蓋夢餘壓, 10.8) 更多 | ||||||
N/A | 23 | 憲齋觸鑰艱顧膚觸醖壓(憲簾願製顧鏇糧遞積蓋) = 積醖鏇鬱壓願齋繭製築 窪夢遞鏇築憲範蓋憲鏇 (艱遞夢觸鬱壓網膚憲衊 ) 更多 | - | 2006-11-01 | |||
Placebo | 憲齋觸鑰艱顧膚觸醖壓(憲簾願製顧鏇糧遞積蓋) = 顧顧糧構鹽餘廠齋鏇衊 窪夢遞鏇築憲範蓋憲鏇 (艱遞夢觸鬱壓網膚憲衊 ) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用